Teva Pharmaceuticals to make 1,000 of its employees redundant following its acquisition of US-based Cephalon last month.
The cuts represent approximately 27% of Cephalon’s entire workforce.
Go deeper with GlobalData
The company has expected to gather at least $500m in synergies as a result of the acquisition.
The layoffs will not affect Teva’s operations in its home nation Israel, but instead in the US and Europe.
Teva CEO Shlomo Yanai is currently in the US overseeing the merger of Cephalon’s interests.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
